Do analysts prefer BBLG or VERO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bone Biologics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Venus Concept 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts rate VERO or BJDX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Venus Concept 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Bluejay Diagnostics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts recommend VERO or DYNT?

Given Dynatronics' higher possible upside, analysts clearly believe Dynatronics is more favorable than Venus Concept. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Venus Concept 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Dynatronics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is VERO or DYNT more profitable?

Dynatronics has a net margin of -8.35% compared to Venus Concept's net margin of -92.76%. Dynatronics' return on equity of -41.81% beat Venus Concept's return on equity. Company Net Margins Return on Equity Return on Assets Venus Concept -92.76% -1,904.25% -85.22% Dynatronics -8.35% -41.81% -9.56%

Do analysts recommend BIOL or VERO?

Given BIOLASE's higher probable upside, equities analysts clearly believe BIOLASE is more favorable than Venus Concept. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BIOLASE 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Venus Concept 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is BIOL or VERO more profitable?

BIOLASE has a net margin of -41.65% compared to Venus Concept's net margin of -92.76%. BIOLASE's return on equity of -1,782.73% beat Venus Concept's return on equity. Company Net Margins Return on Equity Return on Assets BIOLASE -41.65% -1,782.73% -55.31% Venus Concept -92.76% -1,904.25% -85.22%

Venus Concept (VERO) Competitors

$0.31 0.00 (0.00%)

As of 08/7/2026

Compare

VERO vs. BBLG, BJDX, DYNT, BIOL, and RBOT

Should you buy Venus Concept stock or one of its competitors? Venus Concept's main competitors and comparable companies include Bone Biologics (BBLG), Bluejay Diagnostics (BJDX), Dynatronics (DYNT), BIOLASE (BIOL), and Vicarious Surgical (RBOT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Venus Concept compare to Bone Biologics?

Bone Biologics (NASDAQ:BBLG) and Venus Concept (NASDAQ:VERO) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, media sentiment, earnings, risk and analyst recommendations.

In the previous week, Bone Biologics had 1 more articles in the media than Venus Concept. MarketBeat recorded 1 mentions for Bone Biologics and 0 mentions for Venus Concept. Bone Biologics' average media sentiment score of 0.00 equaled Venus Concept'saverage media sentiment score.

Company	Overall Sentiment
Bone Biologics	Neutral
Venus Concept	Neutral

Bone Biologics has a net margin of 0.00% compared to Venus Concept's net margin of -92.76%. Bone Biologics' return on equity of -50.47% beat Venus Concept's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bone Biologics	N/A	-50.47%	-47.40%
Venus Concept	-92.76%	-1,904.25%	-85.22%

Bone Biologics has higher earnings, but lower revenue than Venus Concept. Bone Biologics is trading at a lower price-to-earnings ratio than Venus Concept, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bone Biologics	N/A	N/A	-$3.11M	-$2.27	N/A
Venus Concept	$58.88M	0.01	-$47M	-$48.84	N/A

Bone Biologics has a beta of 0.93, meaning that its stock price is 7% less volatile than the broader market. Comparatively, Venus Concept has a beta of -0.06, meaning that its stock price is 106% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bone Biologics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Venus Concept	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

34.3% of Bone Biologics shares are owned by institutional investors. Comparatively, 87.4% of Venus Concept shares are owned by institutional investors. 5.6% of Bone Biologics shares are owned by insiders. Comparatively, 28.0% of Venus Concept shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Bone Biologics beats Venus Concept on 7 of the 11 factors compared between the two stocks.

How does Venus Concept compare to Bluejay Diagnostics?

Venus Concept (NASDAQ:VERO) and Bluejay Diagnostics (NASDAQ:BJDX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, valuation, risk and media sentiment.

In the previous week, Venus Concept's average media sentiment score of 0.00 equaled Bluejay Diagnostics'average media sentiment score.

Company	Overall Sentiment
Venus Concept	Neutral
Bluejay Diagnostics	Neutral

87.4% of Venus Concept shares are held by institutional investors. Comparatively, 18.5% of Bluejay Diagnostics shares are held by institutional investors. 28.0% of Venus Concept shares are held by company insiders. Comparatively, 6.1% of Bluejay Diagnostics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Venus Concept	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Bluejay Diagnostics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Bluejay Diagnostics has lower revenue, but higher earnings than Venus Concept. Bluejay Diagnostics is trading at a lower price-to-earnings ratio than Venus Concept, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Venus Concept	$58.88M	0.01	-$47M	-$48.84	N/A
Bluejay Diagnostics	N/A	N/A	-$6.85M	-$11.63	N/A

Bluejay Diagnostics has a net margin of 0.00% compared to Venus Concept's net margin of -92.76%. Bluejay Diagnostics' return on equity of -144.27% beat Venus Concept's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Venus Concept	-92.76%	-1,904.25%	-85.22%
Bluejay Diagnostics	N/A	-144.27%	-115.00%

Venus Concept has a beta of -0.06, indicating that its stock price is 106% less volatile than the broader market. Comparatively, Bluejay Diagnostics has a beta of 0.89, indicating that its stock price is 11% less volatile than the broader market.

Summary

Venus Concept and Bluejay Diagnostics tied by winning 5 of the 10 factors compared between the two stocks.

How does Venus Concept compare to Dynatronics?

Venus Concept (NASDAQ:VERO) and Dynatronics (NASDAQ:DYNT) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, profitability, analyst recommendations, dividends, media sentiment and risk.

Venus Concept has a beta of -0.06, meaning that its share price is 106% less volatile than the broader market. Comparatively, Dynatronics has a beta of 0.31, meaning that its share price is 69% less volatile than the broader market.

Given Dynatronics' higher possible upside, analysts clearly believe Dynatronics is more favorable than Venus Concept.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Venus Concept	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Dynatronics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Dynatronics has lower revenue, but higher earnings than Venus Concept. Venus Concept is trading at a lower price-to-earnings ratio than Dynatronics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Venus Concept	$58.88M	0.01	-$47M	-$48.84	N/A
Dynatronics	$33.60M	0.00	-$2.70M	-$1.35	N/A

In the previous week, Dynatronics had 1 more articles in the media than Venus Concept. MarketBeat recorded 1 mentions for Dynatronics and 0 mentions for Venus Concept. Venus Concept's average media sentiment score of 0.00 equaled Dynatronics'average media sentiment score.

Company	Overall Sentiment
Venus Concept	Neutral
Dynatronics	Neutral

Dynatronics has a net margin of -8.35% compared to Venus Concept's net margin of -92.76%. Dynatronics' return on equity of -41.81% beat Venus Concept's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Venus Concept	-92.76%	-1,904.25%	-85.22%
Dynatronics	-8.35%	-41.81%	-9.56%

87.4% of Venus Concept shares are owned by institutional investors. Comparatively, 4.2% of Dynatronics shares are owned by institutional investors. 28.0% of Venus Concept shares are owned by company insiders. Comparatively, 2.9% of Dynatronics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Dynatronics beats Venus Concept on 8 of the 13 factors compared between the two stocks.

How does Venus Concept compare to BIOLASE?

BIOLASE (NASDAQ:BIOL) and Venus Concept (NASDAQ:VERO) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, dividends, profitability, valuation, analyst recommendations, institutional ownership and media sentiment.

BIOLASE has a beta of 0.67, indicating that its stock price is 33% less volatile than the broader market. Comparatively, Venus Concept has a beta of -0.06, indicating that its stock price is 106% less volatile than the broader market.

BIOLASE has higher earnings, but lower revenue than Venus Concept. Venus Concept is trading at a lower price-to-earnings ratio than BIOLASE, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BIOLASE	$48.83M	0.00	-$20.63M	-$14.94	N/A
Venus Concept	$58.88M	0.01	-$47M	-$48.84	N/A

8.8% of BIOLASE shares are owned by institutional investors. Comparatively, 87.4% of Venus Concept shares are owned by institutional investors. 0.3% of BIOLASE shares are owned by company insiders. Comparatively, 28.0% of Venus Concept shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, BIOLASE's average media sentiment score of 0.00 equaled Venus Concept'saverage media sentiment score.

Company	Overall Sentiment
BIOLASE	Neutral
Venus Concept	Neutral

Given BIOLASE's higher probable upside, equities analysts clearly believe BIOLASE is more favorable than Venus Concept.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BIOLASE	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Venus Concept	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

BIOLASE has a net margin of -41.65% compared to Venus Concept's net margin of -92.76%. BIOLASE's return on equity of -1,782.73% beat Venus Concept's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BIOLASE	-41.65%	-1,782.73%	-55.31%
Venus Concept	-92.76%	-1,904.25%	-85.22%

Summary

BIOLASE beats Venus Concept on 8 of the 12 factors compared between the two stocks.

How does Venus Concept compare to Vicarious Surgical?

Vicarious Surgical (NYSE:RBOT) and Venus Concept (NASDAQ:VERO) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, profitability, analyst recommendations, institutional ownership, valuation and dividends.

47.3% of Vicarious Surgical shares are owned by institutional investors. Comparatively, 87.4% of Venus Concept shares are owned by institutional investors. 11.1% of Vicarious Surgical shares are owned by insiders. Comparatively, 28.0% of Venus Concept shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Vicarious Surgical presently has a consensus target price of $7.00, indicating a potential upside of 10,652.69%. Given Vicarious Surgical's stronger consensus rating and higher possible upside, equities research analysts plainly believe Vicarious Surgical is more favorable than Venus Concept.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vicarious Surgical	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Venus Concept	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Venus Concept has higher revenue and earnings than Vicarious Surgical. Vicarious Surgical is trading at a lower price-to-earnings ratio than Venus Concept, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vicarious Surgical	N/A	N/A	-$63.22M	-$6.69	N/A
Venus Concept	$58.88M	0.01	-$47M	-$48.84	N/A

In the previous week, Vicarious Surgical's average media sentiment score of 0.00 equaled Venus Concept'saverage media sentiment score.

Company	Overall Sentiment
Vicarious Surgical	Neutral
Venus Concept	Neutral

Vicarious Surgical has a net margin of 0.00% compared to Venus Concept's net margin of -92.76%. Vicarious Surgical's return on equity of -184.13% beat Venus Concept's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vicarious Surgical	N/A	-184.13%	-112.50%
Venus Concept	-92.76%	-1,904.25%	-85.22%

Vicarious Surgical has a beta of 1.92, indicating that its share price is 92% more volatile than the broader market. Comparatively, Venus Concept has a beta of -0.06, indicating that its share price is 106% less volatile than the broader market.

Summary

Vicarious Surgical and Venus Concept tied by winning 6 of the 12 factors compared between the two stocks.

Get Venus Concept News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VERO vs. The Competition

Export

Metric	Venus Concept	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$442K	$5.82B	$7.02B	$12.98B
Dividend Yield	N/A	1.78%	2.58%	10.07%
P/E Ratio	-0.01	24.72	269.20	24.72
Price / Sales	0.01	61.02	588.81	98.32
Price / Cash	N/A	33.55	28.89	37.42
Price / Book	0.07	6.21	11.27	6.42
Net Income	-$47M	$147.87M	$3.45B	$347.03M
7 Day Performance	N/A	1.05%	1.92%	0.69%
1 Month Performance	N/A	1.62%	-0.58%	-0.90%
1 Year Performance	-87.38%	5.33%	75.49%	21.87%

Venus Concept Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VERO Venus Concept	N/A	$0.31 flat	N/A	N/A	$442K	$58.88M	N/A	410
BBLG Bone Biologics	0.8789 of 5 stars	$0.95 +5.0%	N/A	-62.2%	$1.63M	N/A	N/A	2	Upcoming Earnings
BJDX Bluejay Diagnostics	0.6968 of 5 stars	$1.00 +6.1%	N/A	-82.4%	$980K	N/A	N/A	9	Gap Down
DYNT Dynatronics	N/A	N/A	N/A	N/A	$653K	$33.60M	N/A	200	News Coverage
BIOL BIOLASE	N/A	N/A	N/A	N/A	$581K	$48.83M	N/A	160

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VERO) was last updated on 8/11/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Venus Concept (VERO) Competitors

VERO vs. BBLG, BJDX, DYNT, BIOL, and RBOT

How does Venus Concept compare to Bone Biologics?

Summary

How does Venus Concept compare to Bluejay Diagnostics?

Summary

How does Venus Concept compare to Dynatronics?

Summary

How does Venus Concept compare to BIOLASE?

Summary

How does Venus Concept compare to Vicarious Surgical?

Summary

Media Sentiment Over Time

VERO vs. The Competition

Venus Concept Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Venus Concept (VERO) Competitors

VERO vs. BBLG, BJDX, DYNT, BIOL, and RBOT

How does Venus Concept compare to Bone Biologics?

Does the media prefer BBLG or VERO?

Is BBLG or VERO more profitable?

Which has preferable valuation and earnings, BBLG or VERO?

Which has more volatility and risk, BBLG or VERO?

Do analysts prefer BBLG or VERO?

Do institutionals & insiders believe in BBLG or VERO?

Summary

How does Venus Concept compare to Bluejay Diagnostics?

Does the media refer more to VERO or BJDX?

Do insiders and institutionals have more ownership in VERO or BJDX?

Do analysts rate VERO or BJDX?

Which has stronger earnings & valuation, VERO or BJDX?

Is VERO or BJDX more profitable?

Which has more volatility and risk, VERO or BJDX?

Summary

How does Venus Concept compare to Dynatronics?

Which has more risk & volatility, VERO or DYNT?

Do analysts recommend VERO or DYNT?

Which has preferable earnings and valuation, VERO or DYNT?

Does the media favor VERO or DYNT?

Is VERO or DYNT more profitable?

Do institutionals & insiders hold more shares of VERO or DYNT?

Summary

How does Venus Concept compare to BIOLASE?

Which has more volatility & risk, BIOL or VERO?

Which has better earnings & valuation, BIOL or VERO?

Do insiders & institutionals believe in BIOL or VERO?

Does the media prefer BIOL or VERO?

Do analysts recommend BIOL or VERO?

Is BIOL or VERO more profitable?

Summary

How does Venus Concept compare to Vicarious Surgical?

Do insiders and institutionals believe in RBOT or VERO?

Do analysts recommend RBOT or VERO?

Which has higher valuation & earnings, RBOT or VERO?

Does the media prefer RBOT or VERO?

Is RBOT or VERO more profitable?

Which has more risk and volatility, RBOT or VERO?

Summary

Media Sentiment Over Time

VERO vs. The Competition

Venus Concept Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools